SGMT (Sagimet Biosciences) OCF Margin %: 0.00% (As of Mar. 2026)


SGMT Sagimet Biosciences Inc SGMT
10 GF Score
Price $6.92
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences OCF Margin %?

Sagimet Biosciences SGMT -1.84% 10 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates SGMT with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, Sagimet Biosciences ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Sagimet Biosciences's Cash Flow from Operations for the three months ended in Mar. 2026 was $-8.61 Mil. Sagimet Biosciences's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Sagimet Biosciences's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Sagimet Biosciences's current OCF Yield % is -9.30%.

The historical rank and industry rank for Sagimet Biosciences's OCF Margin % or its related term are showing as below:


During the past 7 years, the highest OCF Margin % of Sagimet Biosciences was -1188.30%. The lowest was -1188.30%. And the median was -1188.30%.

SGMT's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Sagimet Biosciences OCF Margin % Related Terms

Sagimet Biosciences OCF Margin % Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences OCF Margin % Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 -1,188.30 0.00 0.00

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SGMT
10GF Score
Sagimet Biosciences Inc SGMT
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Sagimet Biosciences's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-45.65/0
= %

Sagimet Biosciences's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-8.611/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Sagimet Biosciences (SGMT) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sagimet Biosciences and its competitors. According to the industry distribution chart, Sagimet Biosciences ranks #999999 out of 960 companies in the Biotechnology industry.
Is Sagimet Biosciences' OCF Margin % too high?
Sagimet Biosciences' current OCF Margin % is 0.00%. Based on the distribution chart, Sagimet Biosciences ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' OCF Margin % compare to NGNE and UPB?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #999999 out of 960 companies for OCF Margin %. This places Sagimet Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (SGMT) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Sagimet Biosciences (SGMT), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score

Get the complete analysis for SGMT

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.92
Price